Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Neuro-Oncology Advances|February 22, 2021
Extent of radiological response does not reflect survival in primary central nervous system lymphomaMatthijs van der Meulen, Alida A Postma, Marion Smits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II StudyAnnemieke J M Nieuweboer, Anne-Joy M de Graan, Paul Hamberg, et al.
Cancers|August 23, 2019
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with CabazitaxelIngeborg E de Kruijff, Anieta M Sieuwerts, Wendy Onstenk, et al.
Molecular Oncology|June 11, 2019
AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxelAnieta M Sieuwerts, Wendy Onstenk, Jaco Kraan, et al.
The Lancet. Oncology|January 12, 2019
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyJacoline E C Bromberg, Samar Issa, Katerina Bakunina, et al.
Plos One|January 20, 2026
Drawing cancer chronicles: A qualitative study to evaluate narrative meaning-making over time and in response to a meaning-centred care interventionEmily R E Evans, Niels van Poecke, Maite Portela, et al.
Investigational New Drugs|December 9, 2015
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II studyDidier Meulendijks, Laurens V Beerepoot, Henk Boot, et al.
British Journal of Haematology|July 11, 2019
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON studyPieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, et al.
Cancer|March 13, 2016
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 studyDidier Meulendijks, Jan Willem B de Groot, Maartje Los, et al.
Neuro-Oncology|December 1, 2023
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 studyJacoline E C Bromberg, Samar Issa, Bronno van der Holt, et al.
Pageof 5